Nature 437, 764-769 (29 September 2005) | doi:10.1038/nature03956; Received 9 April 2005; Accepted 24 June 2005

Structural basis of West Nile virus neutralization by a therapeutic antibody

Grant E. Nybakken1, Theodore Oliphant2, Syd Johnson5, Stephen Burke5, Michael S. Diamond1,2,4 & Daved H. Fremont1,3

  1. Departments of Pathology & Immunology,
  2. Molecular Microbiology,
  3. Biochemistry and Molecular Biophysics, and
  4. Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
  5. MacroGenics, Rockville, Maryland 20850, USA

Correspondence to: Daved H. Fremont1,3 Correspondence and requests for materials should be addressed to D.H.F. (Email: Fremont@wustl.edu). E16 antibody sequences have been deposited under GenBank accession numbers DQ083997 (VH) and DQ083998 (VL). Coordinates for the E16 Fab–West Nile virus DIII complex have been deposited under accession code RCSB 1ZTX.

West Nile virus is a mosquito-borne flavivirus closely related to the human epidemic-causing dengue, yellow fever and Japanese encephalitis viruses1. In establishing infection these icosahedral viruses undergo endosomal membrane fusion catalysed by envelope glycoprotein rearrangement of the putative receptor-binding domain III (DIII) and exposure of the hydrophobic fusion loop2, 3, 4. Humoral immunity has an essential protective function early in the course of West Nile virus infection5, 6. Here, we investigate the mechanism of neutralization by the E16 monoclonal antibody that specifically binds DIII. Structurally, the E16 antibody Fab fragment engages 16 residues positioned on four loops of DIII, a consensus neutralizing epitope sequence conserved in West Nile virus and distinct in other flaviviruses. The E16 epitope protrudes from the surface of mature virions in three distinct environments7, and docking studies predict Fab binding will leave five-fold clustered epitopes exposed. We also show that E16 inhibits infection primarily at a step after viral attachment, potentially by blocking envelope glycoprotein conformational changes. Collectively, our results suggest that a vaccine strategy targeting the dominant DIII epitope may elicit safe and effective immune responses against flaviviral diseases.


These links to content published by NPG are automatically generated.


Flavivirus DNA vaccine with a kick

Nature Biotechnology News and Views (01 May 2008)

Research Highlights

Nature Biotechnology News and Views (01 Apr 2006)

See all 5 matches for News And Views